<DOC>
	<DOC>NCT00002216</DOC>
	<brief_summary>The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.</brief_summary>
	<brief_title>A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment</brief_title>
	<detailed_description>In this open-label study antiretroviral-naive patients are randomized to one of two drug regimens: Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II: Nelfinavir and Combivir.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Patients must have: CD4 count &gt; 50. HIV RNA &gt; 5,000. No active AIDS (excluding CD4 count &lt; 200). Ability to comply with dosing schedule and protocol evaluations. Prior Medication: Allowed: 3TC or any protease inhibitor, if &lt; 1 week of therapy. Other nucleoside analogs, if &lt; 4 weeks of therapy. Exclusion Criteria Coexisting Condition: Patients with any of the following symptoms or conditions are excluded: Active AIDS (not including CD4 count &lt; 200). Malabsorption syndrome affecting drug absorption. Concurrent Medication: Excluded: Enrollment in any other investigational drug protocol. Prior Medication: Excluded: Nonnucleoside reverse transcriptase inhibitors.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>